GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rheumatoid Arthritis overview

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by inflammation of the synovium, the lining of joints. This leads to pain, stiffness, swelling, and joint deformity, often affecting multiple joints symmetrically. RA can also involve other organs, causing systemic symptoms like fatigue, fever, and weight loss. Its exact cause remains unknown, but genetic predisposition and environmental factors are implicated. Early diagnosis and treatment are crucial to prevent joint damage and disability. Treatment typically involves a combination of medications such as disease-modifying antirheumatic drugs (DMARDs), biologic agents, and nonsteroidal anti-inflammatory drugs (NSAIDs), along with physical therapy and lifestyle modifications.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

G lobalDat a, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.